Pancreatic Cancer Research

ResearcherInha UniversityNo recent work listed

Mi Kwon Son

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5062995205. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 13

  1. Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2021.145↗
  2. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Co-author DOI 10.1016/j.canlet.2021.03.015↗
  3. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.09.013↗
  4. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.03.009↗
  5. Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (201… Co-author DOI 10.1016/j.canlet.2017.06.019↗
  6. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22850↗
  7. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12871↗
  8. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2014.07.001↗
  9. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2363↗
  10. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2435↗
  11. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2013.01.007↗
  12. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.04.002↗
  13. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/or.2013.2517↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong Hua Yan · 13 shared papers, 2013–2022 · strength 0.82
  2. Kyung Hee Jung · 13 shared papers, 2013–2022 · strength 0.82
  3. Soon‐Sun Hong · 12 shared papers, 2013–2022 · strength 0.77
  4. Zhenghuan Fang · 7 shared papers, 2014–2022 · strength 0.52
  5. Jung Hee Park · 5 shared papers, 2016–2022 · strength 0.43
  6. Yeo Wool Kang · 4 shared papers, 2017–2022 · strength 0.38
  7. Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
  8. Ji Eun Lee · 3 shared papers, 2017–2021 · strength 0.24
  9. Sungwoo Hong · 5 shared papers, 2013–2016 · strength 0.22
  10. Ye-Lim Ryu · 4 shared papers, 2013–2014 · strength 0.16
  11. Ji Eun Lee · 1 shared paper, 2022 · strength 0.14
  12. Chae‐Ok Yun · 2 shared papers, 2017 · strength 0.14
  13. Marufa Rumman · 1 shared paper, 2016 · strength 0.05
  14. Soon‐Sun Hong · 1 shared paper, 2014 · strength 0.04
  15. Hee Seung Lee · 1 shared paper, 2013 · strength 0.04
  16. Ju Hyeon Seo · 1 shared paper, 2013 · strength 0.04
  17. Sun‐Mi Yun · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.